Stock Splits
By The Online Investor Staff, updated Tue., Sep. 17, 9:21 AM
| This Slide: #8 of 25 |
Slide #8. Neuralstem, Inc. (NASDAQ:CUR) — 1 for 20 Reverse Split
Announced:
7/16/2019
Stock Split:
1 for 20
Record Date:
7/16/2019
Pay Date:
7/17/2019
CUR Optionable?:
Yes
Neuralstem is a clinical stage biopharmaceutical company that is utilizing its proprietary human neural stem cell technology to create a platform of therapies for the treatment of central nervous system diseases. Co.'s technology platform has produced four key assets, two in clinical development and two in preclinical development: its NSI-566 stem cell therapy program (clinical stage) for treatment of paralysis, NSI-189 small molecule program (clinical stage) for Major Depressive Disorder and NSI-532 for Alzheimer's Disease and NSI-577 indicated for potential use in treatment of human demyelinating diseases, both of which are second-generation stem cell therapy programs (preclinical stage). 
CUR Detailed Information Page & Split History »
|
|||||||||||||||||||||
Open the CUR Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 94th percentile
(ranked higher than approx. 94% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
